KCKelly Cleland

Kelly Cleland

*This is an algorithmically generated author record based on publicly available information.

Kelly Cleland has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using autoregressive integrated moving average models for time series analysis of observational data

    by Brandon Wagner, Kelly Cleland

    Much of the data that we collect about the world around us—stock prices, unemployment rates, party identification—are measured repeatedly over time. By failing to account for the linked and time dependent nature of these data, common analytic techniques may misrepresent their internal structure. If we wish to describe patterns over time or forecast values beyond the observation period, we need to account for how current values may depend on previous values, trends may exist in the data, or data may vary seasonally. To visualize this, consider an electrocardiogram. The readings expected at a given moment depend not only on the preceding values but also on the position within the entire cycle. For example, following the P wave, we would expect to see the QRS complex. The assumption that each reading is unaffected by preceding values would be valid only in the most distressing circumstances (that is, during fibrillation or after death).


  • Open Access

    Retail demand for emergency contraception in United States following New Year holiday: time series study

    by Brandon Wagner, Kelly Cleland

    Objective To estimate the increase in sales of emergency contraception following the New Year’s Eve/New Year’s Day holiday. Design Time series analysis using autoregressive integrated moving average (ARIMA) model. Setting Traditional (that is, “bricks and mortar”) retail outlets—grocery stores, drug stores, mass merchandisers, club stores, dollar stores, and military outlets—in the United States from 2016 to 2022. Data source Marketing data on weekly aggregated sales of items classified as emergency contraception gathered between 2016 and 2022 (n=362). On the basis of dates, weeks were classified as following the New Year holiday (n=6) or not (n=356). Main outcome measure Weekly sales of levonorgestrel emergency contraception per 1000 women of reproductive age in the US population. Results Sales of levonorgestrel emergency contraception significantly increased after the New Year holiday (0.63 (95% confidence interval 0.58 to 0.69) unit increase per 1000 women aged 15-44). Holidays that share some aspects of the elevated risks of unprotected sexual intercourse with the New Year holiday (Valentine’s Day, St Patrick’s Day, US Independence Day) were associated with increased sales, albeit to a lesser degree, with respective sales increases per 1000 women aged 15-44 of 0.31 (0.25 to 0.38), 0.14 (0.06 to 0.23), and 0.20 (0.11 to 0.29). Holidays without these expectations (Easter, Mother’s Day, Father’s Day) were not significantly associated with sales of levonorgestrel emergency contraception. Conclusions Increased sales of emergency contraception following the New Year’s holiday suggest that this period is associated with increased risks of unprotected vaginal intercourse compared with other holidays. Targeting behavioral risks, prevention strategies to mitigate sexual violence, and improving access to contraception around holidays may limit the risks associated with unprotected vaginal intercourse.


  • Progestin intrauterine devices versus copper intrauterine devices for emergency contraception

    by Shaalini Ramanadhan, Norman Goldstuck, Jillian T Henderson, Yan Che, Kelly Cleland, Laura E Dodge, Alison Edelman

    Background The copper intrauterine device (Cu‐IUD) is a highly effective method of contraception that can also be used for emergency contraception (EC). It is the most effective form of EC, and is more effective than other existing oral regimens also used for EC. The Cu‐IUD provides the unique benefit of providing ongoing contraception after it is inserted for EC; however, uptake of this intervention has been limited. Progestin IUDs are a popular method of long‐acting, reversible contraception. If these devices were also found to be effective for EC, they would provide a critical additional option for women. These IUDs could not only provide EC and ongoing contraception, but additional non‐contraceptive benefits, including a reduction in menstrual bleeding, cancer prevention, and pain management. Objectives To examine the safety and effectiveness of progestin‐containing IUDs for emergency contraception, compared with copper‐containing IUDs, or compared with dedicated oral hormonal methods. Search methods We considered all randomized controlled trials and non‐randomized studies of interventions that compared outcomes for individuals seeking a levonorgestrel IUD (LNG‐IUD) for EC to a Cu‐IUD or dedicated oral EC method. We considered full‐text studies, conference abstracts, and unpublished data. We considered studies irrespective of their publication status and language of publication. Selection criteria We included studies comparing progestin IUDs with copper‐containing IUDs, or oral EC methods for emergency contraception. Data collection and analysis We systematically searched nine medical databases, two trials registries, and one gray literature site. We downloaded all titles and abstracts retrieved by electronic searching to a reference management database, and removed duplicates. Three review authors independently screened titles, abstracts, and full‐text reports to determine studies eligible for inclusion. We followed standard Cochrane methodology to assess risk of bias, and analyze and interpret the data. We used GRADE methodology to assess the certainty of the evidence. Main results We included only one relevant study (711 women); a randomized, controlled, non‐inferiority trial comparing LNG‐IUDs to Cu‐IUDs for EC, with a one‐month follow‐up. With one study, the evidence was very uncertain for the difference in pregnancy rates, failed insertion rates, expulsion rates, removal rates and the difference in the acceptability of the IUDs. There was also uncertain evidence suggesting the Cu‐IUD may slightly increase rates of cramping and the LNG‐IUD may slightly increase bleeding and spotting days. Authors' conclusions This review is limited in its ability to provide definitive evidence regarding the LNG‐IUD’s equivalence, superiority, or inferiority to the Cu‐IUD for EC. Only one study was identified in the review, which had possible risks of bias related to randomization and rare outcomes. Additional studies are needed to provide definitive evidence related to the effectiveness of the LNG‐IUD for EC.


  • Now is the time to safeguard access to emergency contraception as abortion restrictions sweep the United States

    by Kelly Cleland, Bhavik Kumar, Nikita Kakkad, Jasmine Shabazz, Nicola R. Brogan, Mara K. Gandal-Powers, Robyn Elliott, Rebecca Stone, David K. Turok


  • Progestin-containing versus copper intrauterine devices for emergency contraception

    by Kelly Cleland, Yan Che, Laura E Dodge, Alison Edelman, Norman Goldstuck, Shaalini Ramanadhan


  • “My BMI is too high for Plan B.” A changing population of women seeking ulipristal acetate emergency contraception online

    by Kelly Cleland, Brandon Wagner, Nicole K. Smith, James Trussell

    Emergency contraceptive (EC) pills may be less effective for women with higher body mass index (BMI), but little is known about public response to the fact that EC may lose efficacy as weight increases. In November 2013, European authorities changed the label for a levonorgestrel EC product to warn of a reduction in effectiveness for women with higher BMI, garnering significant media coverage in the United States. Ulipristal acetate (UPA) EC may be more effective than levonorgestrel for women with BMI levels designated as obese. Among 8,019 women who received UPA from the online pharmacy KwikMed from 2011 to 2015 and self-reported their height, weight and reasons for seeking UPA online, we analyzed changes in the proportion of women in different BMI categories before and after the label change. For the 25 month-period after the label change, the proportion of women in the obese category rose by 26.7 percentage points relative to the 35 months before (B = 0.2665, p < .01). Mean BMI (25.5 versus 29.4, p < .001) and average weight (148.6 pounds versus 175.5 pounds, p < .001) of users were higher after the label change. Some women appear to have acted on the information that EC efficacy may be associated with body weight.


  • Open Access

    Emergency Contraception Counseling in California Community Pharmacies: A Mystery Caller Study

    by Lindsay Ditmars, Sally Rafie, Gellan Kashou, Kelly Cleland, Lisa Bayer, Tracey A. Wilkinson

    This study was conducted to determine which emergency contraception (EC) methods are offered by community pharmacists in response to patient calls. Female mystery callers called all community pharmacies in two California cities using standardized scripts. The callers inquired about options available to prevent pregnancy after sex and whether that method was available at the pharmacy, using follow-up probes if necessary. A total of 239 calls were completed in San Diego (n = 127, 53%) and San Francisco (n = 112, 47%). Pharmacists indicated availability at most sites (n = 220, 92%) with option(s) reported as levonorgestrel only (LNG; n = 211, 88.3%), both ulipristal acetate (UPA) and LNG (n = 4, 1.6%), UPA only (n = 1, 0.4%), or non-specific EC (n = 4, 1.7%). Nineteen pharmacies (7.9%) did not have EC available on the day of the call. Following additional probing, some pharmacists discussed UPA (n = 49, 20.5%) or the copper intrauterine device (n = 1, 0.4%) as EC options. LNG EC products were available same-day in 90.1% of pharmacies, whereas UPA was available same-day in 9.6% of pharmacies. The majority of pharmacies called in this study offered and stocked at least one EC option, but the focus of discussions was on LNG and matched what was in stock and available.


  • Open Access

    State of emergency contraception in the U.S., 2018

    by Kristin O. Haeger, Jacqueline Lamme, Kelly Cleland

    Emergency contraception is indicated in instances of unprotected sexual intercourse, including reproductive coercion, sexual assault, and contraceptive failure. It plays a role in averting unintended pregnancies due to inconsistent use or non-use of contraception. Options for emergency contraception vary by efficacy as well as accessibility within the U.S. This paper provides an overview of levonorgestrel (Plan B One-Step and generic counterparts), ulipristal acetate (sold as ella), and the copper intrauterine device (IUD, sold as ParaGard), including the mechanisms of action, administration, efficacy, drug interactions, safety, side effects, advantages, and drawbacks. It will also review current misconceptions about emergency contraception and access for subpopulations, including adolescents, immigrants, survivors of sexual assault, rural populations, and military/veteran women. This paper will address barriers such as gaps in knowledge, and financial, health systems, and practice barriers. Continuing areas of research, including the impact of body weight on the efficacy of emergency contraceptive pills and potential interactions between ulipristal acetate and ongoing hormonal contraceptives, are also addressed.


  • The politics of place: Presidential voting patterns and providers' prescription of emergency contraception

    by Kelly Cleland, Brandon Wagner, Pelin Batur, Megan McNamara, Justine Wu, Michael B. Rothberg